Low Complement Factor H-Related 3 (CFHR3) Expression Indicates Poor Prognosis and Immune Regulation in Cholangiocarcinoma

Table 2

The baseline table of clinical information in CCA.

Characteristic	Low expression of CFHR3	High expression of CFHR3	value
	18	18
Age, (%)			1.000
≤65	9 (25%)	8 (22.2%)
>65	9 (25%)	10 (27.8%)
Gender, (%)			0.315
Female	12 (33.3%)	8 (22.2%)
Male	6 (16.7%)	10 (27.8%)
T stage, (%)			0.651
T1	8 (22.2%)	11 (30.6%)
T2	7 (19.4%)	5 (13.9%)
T3	3 (8.3%)	2 (5.6%)
T4	0 (0%)	0 (0%)
N stage, (%)			1.000
N0	14 (45.2%)	12 (38.7%)
N1	3 (9.7%)	2 (6.5%)
M stage, (%)			0.656
M0	15 (45.5%)	13 (39.4%)
M1	2 (6.1%)	3 (9.1%)
Pathologic stage, (%)			0.543
Stage I	8 (22.2%)	11 (30.6%)
Stage II	6 (16.7%)	3 (8.3%)
Stage III	1 (2.8%)	0 (0%)
Stage IV	3 (8.3%)	4 (11.1%)
Histological type, (%)			0.346
Distal	2 (5.6%)	0 (0%)
Hilar/perihilar	1 (2.8%)	3 (8.3%)
Intrahepatic	15 (41.7%)	15 (41.7%)
CA19-9 level, (%)			0.299
Abnormal	9 (30%)	7 (23.3%)
Normal	5 (16.7%)	9 (30%)
Vascular invasion, (%)			0.648
No	16 (47.1%)	13 (38.2%)
Yes	2 (5.9%)	3 (8.8%)
Perineural invasion, (%)			1.000
No	14 (42.4%)	12 (36.4%)
Yes	4 (12.1%)	3 (9.1%)
Age,	60.56 ± 15.45	65.5 ± 9.39	0.254